Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
NATICK, Massachusetts, July 28, 2010 /PRNewswire-FirstCall/ --
- Company Expands Market-leading Family of Neurovascular Stents
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.
The Neuroform EZ Stent System is engineered to provide flexibility and conformability, especially in tortuous brain anatomy. It employs Boston Scientific's proprietary Segmental(TM) Expansion technology, designed to enhance stent anchoring and stability. The product features the proven hybrid cell design of prior-generation Neuroform Stents while incorporating a simplified, single-operator delivery system intended to facilitate preparation, delivery and positioning of the stent.
The first Neuroform EZ Stent was implanted in the U.S. by Demetrius Lopes, M.D., of the Rush University Medical Center in Chicago, and the first European procedure was performed by Professor Laurent Spelle, M.D., Ph.D., at Foundation Rothschild Hospital, Beaujon School of Medicine in Paris.
"The Neuroform EZ Stent System performed well in a very challenging first procedure," said Dr. Lopes. "The smooth transfer of the stent into the catheter, combined with excellent support, stability and visibility, facili